Journal of Diagnostics Concepts & Practice >
The prognostic value of CA9 expression in clear cell renal cell carcinoma
Received date: 2022-05-30
Online published: 2023-07-06
Objective: To evaluate the prognostic value of CA9 in predicting postoperative recurrence, metastasis or survival in patients with clear cell renal cell carcinoma(ccRCC). Methods: The clinical pathological data from 231 patients with ccRCC who underwent radical or partial nephrectomy from January 1, 2017 to December 31, 2020 in Ruijin Hospital,Shanghai Jiao Tong University were retrospectively analyzed. The patients were followed up for the overall survival (OS),disease-free survival (DFS),and tumor recurrence or metastasis. All pathological sections and wax blocks of tumor issue were collected to make tissue microarray, and immunohistochemical analysis of tissue microarray was performed using CA9 polyclonal antibody. SPSS statistical software multivariate Cox and Kaplan-Meier were used to evaluate the correlation of CA9 expression with clinicopathological features, OS and DFS. Results: Of the 231 ccRCC patients had a median follow-up of 37 months (13-54 months). It revealed that postoperative recurrence and/or metastasis occurred in 38 cases, inclu-ding 6 cases with both recurrence and metastasis, 3 cases with only recurrence, 29 cases with only metastasis, and 8 deaths. Among 231 patients, CA9 positive expression rate was 94%(217/231), of which 153 (66%) were with cells stained with CA9 ≥85% and 78 (34%) were stained with CA9 <85%. Chi-square analysis showed that the expression of CA9 was not only correlated with T stage, ISUP nuclear grade, sarcomatoid or rhabdomyoid differentiation, necrosis, capsule invasion, vascular infiltration, but also correlated with tumor recurrence, metastasis and survival status. There was no relationship between CA9 expression and age, sex and tumor location (P>0.05). Univariate Kaplan-Meier analysis and multiva-riate Cox analysis showed that low expression of CA9 (<85%) was a poor prognostic factor for postoperative overall survival (OS) and disease-free survival (DFS) in patients with ccRCC, with hazard ratios of 6.211 (P=0.002) and 8.980 (P<0.001), respectively. Conclusions: In ccRCC, low expression of CA9 is associated with poor OS and DFS, and is an independent risk factor for OS and DFS in postoperative patients with ccRCC, which may serve as a useful prognostic indicator.
XU Jiankun, ZHOU Luting, ZHANG Wenjing, XU Haimin, WANG Chaofu . The prognostic value of CA9 expression in clear cell renal cell carcinoma[J]. Journal of Diagnostics Concepts & Practice, 2023 , 22(01) : 37 -43 . DOI: 10.16150/j.1671-2870.2023.01.006
[1] | HSIEH J J, PURDUE M P, SIGNORETTI S, et al. Renal cell carcinoma[J]. Nat Rev Dis Primers, 2017, 3:17009. |
[2] | SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1):7-34. |
[3] | GRAY R E, HARRIS G T. Renal Cell Carcinoma: Diagnosis and Management[J]. Am Fam Physician, 2019, 99(3):179-184. |
[4] | BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. |
[5] | COHEN H T, MCGOVERN F J. Renal-cell carcinoma[J]. N Engl J Med, 2005, 353(23):2477-2490. |
[6] | KROEGER N, ZIMMERMANN U, BURCHARDT M, et al. Prognostication in localised renal cell carcinoma[J]. Lancet Oncol, 2015, 16(6):603-604. |
[7] | LEIBOVICH B C, HAN K R, BUI M H, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials[J]. Cancer, 2003, 98(12):2566-2575. |
[8] | KLATTE T, ROSSI S H, STEWART G D. Prognostic factors and prognostic models for renal cell carcinoma: a lite-rature review[J]. World J Urol, 2018, 36(12):1943-1952. |
[9] | RENSHAW A A, CHEVILLE J C. Quantitative tumour necrosis is an independent predictor of overall survival in clear cell renal cell carcinoma[J]. Pathology, 2015, 47(1):34-37. |
[10] | TSUI K H, SHVARTS O, SMITH R B, et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria[J]. J Urol, 2000, 163(4):1090-1095. |
[11] | LAM J S, LEPPERT J T, FIGLIN R A, et al. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma[J]. Urology, 2005, 66(5 Suppl):1-9. |
[12] | BUI M H, ZISMAN A, PANTUCK A J, et al. Prognostic factors and molecular markers for renal cell carcinoma[J]. Expert Rev Anticancer Ther, 2001, 1(4):565-575. |
[13] | KIM H L, SELIGSON D, LIU X, et al. Using tumor mar-kers to predict the survival of patients with metastatic renal cell carcinoma[J]. J Urol, 2005, 173(5):1496-1501. |
[14] | IVANOV S, LIAO S Y, IVANOVA A, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer[J]. Am J Pathol, 2001, 158(3):905-919. |
[15] | MAXWELL P H, WIESENER M S, CHANG G W, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis[J]. Nature, 1999, 399(6733):271-275. |
[16] | BUI M H, SELIGSON D, HAN K R, et al. Carbonic anhydrase Ⅸ is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy[J]. Clin Cancer Res, 2003, 9(2):802-811. |
[17] | BENEJ M, PASTOREKOVA S, PASTOREK J. Carbonic anhydrase Ⅸ: regulation and role in cancer[J]. Subcell Biochem, 2014, 75:199-219. |
[18] | TAFRESHI N K, LLOYD M C, BUI M M, et al. Carbonic anhydrase Ⅸ as an imaging and therapeutic target for tumors and metastases[J]. Subcell Biochem, 2014, 75:221-254. |
[19] | ZATOVICOVA M, JELENSKA L, HULIKOVA A, et al. Carbonic anhydrase Ⅸ as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain[J]. Curr Pharm Des, 2010, 16(29):3255-3263. |
[20] | ZHAO Z, LIAO G, LI Y, et al. Prognostic value of carbonic anhydrase Ⅸ immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature[J]. PLoS One, 2014, 9(11):e114096. |
[21] | LEIBOVICH B C, SHEININ Y, LOHSE C M, et al. Carbonic anhydrase Ⅸ is not an independent predictor of outcome for patients with clear cell renal cell carcinoma[J]. J Clin Oncol, 2007, 25(30):4757-4764. |
[22] | SANDLUND J, OOSTERWIJK E, GRANKVIST K, et al. Prognostic impact of carbonic anhydrase Ⅸ expression in human renal cell carcinoma[J]. BJU Int, 2007, 100(3):556-560. |
[23] | PATARD J J, FERGELOT P, KARAKIEWICZ P I, et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma[J]. Int J Cancer, 2008, 123(2):395-400. |
[24] | SOYUPAK B, ERDO?AN S, ERGIN M, et al. CA9 expression as a prognostic factor in renal clear cell carcinoma[J]. Urol Int, 2005, 74(1):68-73. |
[25] | LAGUNA M P. Re: carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up[J]. J Urol, 2014, 191(1):54-55. |
[26] | ZERATI M, LEITE K R, PONTES-JUNIOR J, et al. Carbonic Anhydrase IX is not a predictor of outcomes in non-metastatic clear cell renal cell carcinoma-a digital analysis of tissue microarray[J]. Int Braz J Urol, 2013, 39(4):484-492. |
/
〈 |
|
〉 |